Skip to Content
Merck
  • Clindamycin phosphate 1.2%- tretinoin 0.025% gel: vehicle characteristics, stability, and tolerability.

Clindamycin phosphate 1.2%- tretinoin 0.025% gel: vehicle characteristics, stability, and tolerability.

Cutis (2008-06-12)
James Q Del Rosso, Waranush Jitpraphai, Sanjay Bhambri, Saira Momin
ABSTRACT

An aqueous gel formulation containing solubilized clindamycin phosphate 1.2% and a stable combination of both solubilized and crystalline tretinoin 0.025% (clin/tret) has been evaluated in 3 pivotal phase 3 studies, among other studies including a 52-week trial. The pivotal studies enrolled 4550 participants 12 years and older with mild, moderate, and severe acne vulgaris. The combination clin/tret gel was effective in reducing both inflammatory and noninflammatory lesions and was well-tolerated. This article reviews important vehicle characteristics of the combination gel as well as formulation stability and tolerability data that are potentially clinically relevant.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Retinoic acid, ≥98% (HPLC), powder
Sigma-Aldrich
Clindamycin 2-phosphate, aminoglycoside antibiotic
Supelco
Tretinoin, Pharmaceutical Secondary Standard; Certified Reference Material
Tretinoin, European Pharmacopoeia (EP) Reference Standard
USP
Tretinoin, United States Pharmacopeia (USP) Reference Standard
Supelco
Clindamycin Phosphate, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Clindamycin phosphate, United States Pharmacopeia (USP) Reference Standard
Clindamycin phosphate, European Pharmacopoeia (EP) Reference Standard